Recent News

• 08.20.2025 - TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
• 08.14.2025 - TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
• 07.01.2025 - TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
• 06.30.2025 - TuHURA Biosciences Completes Acquisition of Kineta
• 06.24.2025 - TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
• 06.23.2025 - TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 8-K/A Current report
• 08.12.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 07.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.30.2025 - 8-K Current report
• 06.30.2025 - EX-99.1 EX-99.1